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Abstract
Background: Immunological non-responders (INRs) lacked CD4 increase despite HIV-viremia suppression on
HAART and had an increased risk of disease progression. We assessed immune reconstitution profile upon
intensification with maraviroc in INRs.
Methods: We designed a multi-centric, randomized, parallel, open label, phase 4 superiority trial. We enrolled 97
patients on HAART with CD4+<200/µL and/or CD4+ recovery ≤25% and HIV-RNA<50 cp/mL. Patients were
randomized 1:1 to HAART+maraviroc or continued HAART. CD4+ and CD8+ CD45+RA/RO, Ki67 expression and
plasma IL-7 were quantified at W0, W12 and W48.
Results: By W48 both groups displayed a CD4 increase without a significant inter-group difference. A statistically
significant change in CD8 favored patients in arm HAART+maraviroc versus HAART at W12 (p=.009) and W48 (p=.
025). The CD4>200/µL and CD4>200/µL + CD4 gain ≥25% end-points were not satisfied at W12 (p=.24 and p=.619)
nor at W48 (p=.076 and p=.236). Patients continuing HAART displayed no major changes in parameters of T-cell
homeostasis and activation. Maraviroc-receiving patients experienced a significant rise in circulating IL-7 by W48 (p=.
01), and a trend in temporary reduction in activated HLA-DR+CD38+CD4+ by W12 (p=.06) that was not maintained
at W48.
Conclusions: Maraviroc intensification in INRs did not have a significant advantage in reconstituting CD4 T-cell pool,
but did substantially expand CD8. It resulted in a low rate of treatment discontinuations.
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Introduction
The main goal of the highly active antiretroviral therapy
(HAART) is the complete suppression of HIV replication and
the increase of the CD4+ T cell count.
Some observational studies demonstrated that at least 76%
of patients initiating HAART achieved an undetectable viral
load within 6 months [1], but a percentage of 9%-45% did not
obtain an appropriate recovery of CD4+ T cells [2,3]. This
situation, commonly referred to as immuno-virological
discordance, mainly associated with a low CD4+ nadir, may
lead to an increased risk of progression to AIDS defining illness
and death [4-8].
It has been demonstrated that a lack of CD4 cells recovery
and disease progression may be due to a persistent immune
activation [9-12].
Several attempts of HAART intensification have been carried
out to enhance the CD4 count recovery and the viral replication
control. Some studies, like SILCAAT and ESPRIT,
demonstrated that the use of interleukin IL-2 in association with
antiretroviral therapy yielded no clinical benefit despite a
substantial and sustained increase in the CD4+ cell count [13].
Abacavir, tenofovir, efavirenz and more recently raltegravir
have been used as intensification drugs associated with
HAART with no significant impact on the CD4+ cells rise
[14-16].
One of the last antiretrovirals launched in the clinical arena
was maraviroc (MVC), a CCR5 antagonist, that has been
shown to have anti-inflammatory activity. The drug could have
a potential role in the down-regulation of HIV-associated
chronic inflammation by blocking the recirculation and
trafficking of macrophages and monocyte-derived dendritic
cells [17].
Few studies have been performed with MVC used as an
intensification drug in patients with an insufficient immune
response notwithstanding virological successes [18] and few
observations could be done due to the small number of
enrolled patients. Here we present a multi-centric randomised
trial involving 97 immunological non responder (INR) patients,
where MVC was administered in 47 patients as intensification
treatment with the aim of increasing their CD4 count and
eventually improving their immune competence.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Written informed consent was obtained from all participants.
The study was performed in accordance with The International
Conference on Harmonization Good Clinical Practice
guidelines and applicable local regulatory requirements and
laws.
Study design
This was a multi-centric, randomized, parallel, open label,
phase 4 superiority trial. The study was designed with a 48
week treatment period; enrollment started in April, 2009 and
study completion was in April, 2011. One hundred and two
HIV-1-infected adult patients were enrolled in 20 clinical
centers coordinated by the Department of Biomedical and
Clinical Sciences “Luigi Sacco”, Infectious Diseases Unit,
University of Milan, Italy. Clinical trial identification n.
NCT00884858 (registered on ClinicalTrials.gov).
At the screening visit, safety laboratory tests were conducted
and previous antiretroviral treatment was assessed. Individual
patients data and samples were collected and processed by
each of the 20 participating clinical centers. At the time of
randomization, eligible patients were randomly assigned in a
1:1 ratio to receive MVC for intensification of the current
HAART regimen or HAART alone. The trial required a centre-
stratified block-permuted randomization. The random allocation
sequence was generated by the statistician. Study participants
were enrolled by the physicians at the clinical centers and
study participants were assigned to interventions by the
coordinating center. MVC dose was decided according to the
pharmaceutical company’s indications based on drug-drug
interactions with other antiretrovirals. Plasma HIV-RNA was
amplified with Amplicor HIV-1 Monitor Kit v1.5 and quantified
by ultrasensitive real time PCR; this was performed at the Tor
Vergata University I.D. research laboratory.
Plasma and PBMCs samples were collected at screening,
baseline, week 12, week 24 and week 48. Cell viability after
thawing was assessed measuring 7AAD (Becton Dickinson) by
flow cytometry (FC500 cytometer, Beckman Coulter). Only
cells with viability >70% were used for the subsequent
analyses. T-cells and PBMCs were drawn at the same time of
day in all patients, in order to reduce the effect of diurnal
variation. Tropism test was performed on PBMCs at screening
on the available samples. For sequencing the HIV-1 gp120 V3
domain, HIV-1 DNA was extracted from 200 μL of PBMCs
using a QIAamp DNA Minikit (Qiagen, Hilden, Germany),
following the manufacturer's instructions. The HIV-1 env
fragment including the V3 region was amplified by PCR using
gp-120 primers and the Trugene core reagents kit (Siemens
Healthcare Diagnostics Inc., Deerfield, IL, USA) [19]. Tropism
testing was performed in single and FPR cut-off was 20%. This
analysis was performed at the Luigi Sacco virology laboratory.
Study population
All the enrolled patients were at least 18 years-old, HIV-1
infected adults with a CD4+ count <200/µL and/or CD4+
recovery ≤25% and HIV-RNA constantly <50 cp/mL who had
been experiencing a HAART regimen for at least one year.
Ethics statement
The central ethical approval, as communicated to the Italian
Ministry of Health was provided by the Comitato Etico per la
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Sperimentazione Clinica (IRB) at “Luigi Sacco” Hospital, Milan,
Italy. All the ethics committees/institutional review boards of the
participating centres approved the study protocol. A complete
list of the IRBs is available as a supporting information file.
Efficacy analyses
The study’s primary endpoint involved the evaluation of the
CD4+ cell count change from baseline to week 12 and week
48. In particular we established a simple endpoint that was the
achievement of a CD4+ count > 200 cells/µL at two different
measurements, and a composite endpoint including the
achievement of a CD4 count> 200 cells/µL and a CD4+ cells
recovery >25%. The endpoints were defined completely
satisfied when HIV-RNA remained constantly <50 copies/mL
over time.
Flow cytometry
Lymphocyte surface phenotypes were evaluated by flow
cytometry on frozen PBMCs (FC500; Beckman Coulter,
Hialeah, FL), with the following fluorochrome-labelled
antibodies: CD4-PE-Cy7, CD8-PE-Cy5, CD38-PE, HLA-DR-
FITC, CD127-PE (Instrumentation Laboratory, Milan, Italy),
CD45RA-FITC, CD62L-PE, Ki67-FITC, 7-AAD (Becton
Dickinson Italia, Milan, Italy). We measured activation (HLA-
DR/CD38) proliferation (Ki67), differentiation (CD127) and
maturation (CD45RA/CD62L) on CD4+ and CD8+ T-cells. The
following combinations were used: CD4/CD8/CD38/HLA-DR,
CD8/CD4/Ki67, CD8/CD4/CD127 and CD8/CD4/CD45RA/
CD62L. All immunological analyses were performed in the
Laboratory at the Clinic of Infectious Diseases, University of
Milano, San Paolo “Hospital”. The laboratory is fully equipped
with all the reagents and supplies required for processing and
studying PBMCs and plasma samples.
ELISA assays
Plasma levels of Interleukin (IL)-7 were quantified by
commercially available ELISA (R&D System, Minneapolis,
MN), according to manufacturer's instructions.
Statistical analyses
We hypothesized 5% of “responder” patients in the control
arm and δ = 20% in the immunological response between the 2
arms favoring the maraviroc arm (responder patients in the
maraviroc arm = 25%) at week 48. For this superiority study we
set the power as 1-β=80% with one-side α=0.05, thus 50
patients per arm were necessary, after considering protocol
and screening violations and subjects lost to follow-up.
Comparison of CD4+ and CD8+ count between the study arms
A and B and at the different time-points were assessed by t-
test for independent and dependent samples respectively in an
intention to treat (ITT) analysis. Statistical evaluation of simple
and composite endpoints was analyzed by binary logistic
regression models for the odds ratio estimation and the related
95% confidence intervals. Odds ratios of the MVC arm was
also controlled in the regression models for CD4+ counts at
baseline, due to unbalancing though not statistically significant,
of this parameter in the two study arms. Statistical significance
level was estimated by Wald test and was set at .05 for all of
the analyses. In the per-protocol (PP) analysis, patients who
dropped the study or switched treatment were included until
their last observation in the randomization arm. Baseline
characteristics were collected and analyzed through chi-
square, Fisher’s exact test and Mann Whitney U non-
parametric test.
Immunological parameters at baseline (T0), after 12 (w12)
and 48 weeks (w48) of MVC intensification were analyzed with
GraphPad 5 PRISM software (version 5). All continuous
variables were presented as median and interquartile ranges
(25th-75th percentile). The Mann Whitney U test was used for
the comparison of immunological parameters (CD127,
CD45RA, Ki67, HLA-DR, CD38 on CD4 and CD8 and plasma
IL-7) between the 2 groups (ARM A vs ARM B). Wilcoxon
signed-rank test was used to assess changes over time in the
immunological parameters (CD127, CD45RA, Ki67, HLA-DR,
CD38 on CD4 and CD8 and plasma IL-7) within the same
study group (baseline vs W12 vs W48). All tests were 2-sided
and differences were considered statistically significant at
p<0.05. Bonferroni correction was applied to data of activation
markers to account for test multiplicity.
Results
Population characteristics and patients disposition
Of the 102 adult HIV-1 infected patients screened, 97
patients were enrolled in the study. 47 patients were
randomized in arm A (HAART + MVC) and 50 in arm B
(HAART). Recruitment took place from April, 2009 to April,
2010 and follow-up lasted for another 48 weeks.
Twenty patients (11 in arm A and 9 in arm B) abandoned the
study over time. Reasons for discontinuation were: patient’s
choice (arm A: 6 patients vs arm B: 6 patients), adverse events
(arm A: 2, arm B: 1) clinician’s choice (arm A: 2 vs arm B: 1)
and lack of compliance (arm A: 1, arm B: 1) [Figure 1]. In
particular, in arm A the side effects which caused the drop out
from the study and the interruption of MVC in 2 patients where
there was an onset of a Moskowitz-like syndrome in
autoimmune thrombocytopenia [20]. and an allergic
angioedema. The adverse event in arm B was diabetes
mellitus type 2 and metabolic toxicity. Six patients changed
their HAART during the 48 week follow up (physician’s choice,
virologic failure, or adverse events): 5 in arm A and 1 in arm B.
No clinical progression nor IRIS onset was observed. Out of
the original 97 patients randomized, 90 (45 in each arm) had a
complete dataset at 48 weeks and formed the final ITT analysis
population. Baseline characteristics of the study population are
summarized in Table 1. Thirty-six patients in arm A and forty-
one patients in arm B (77 patients) were available for the PP
analysis; in this analysis the median CD4 cell count at baseline
was 191 cell/ µL in arm A and 170 cell/ µL in arm B and the
median CD8 cell count at baseline was 566 cell/ µL in arm A
and 731 cell/ µL in arm B.
T cell CD4+ and CD8+ count
CD4 counts used for the ITT analysis ( 90 patients) are
shown in Figure 2A. In both arms a slight increase of the CD4+
MVC in HIV+ Immunological Non-Responders
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count was registered (arm A: +26.5 cells/µL at week 12 and
+34 cells/µL from baseline at week 48 and arm B: +24 cells/µL
at week 12 and +15 cells/ µL at week 48) but no statistical
significance was seen between the two arm at week 12 (p=
0.283) and week 48 (p=0.991) [Figure 2B]. Similar results were
observed in the PP analysis (arm A: +26.5 cells/µL at week 12,
+34 cells/µL at week 48, arm B:+20 cells/µL at week 12, +20
cells/µL at week 48, p= 0.200 between the two arms at week
12 and p= 0.637 at week 48).
CD8+ cell count was also evaluated at baseline, week 12
and week 48 in the ITT analysis [Figure 2C]. A significant
increase of the CD8+ count was obtained in the intensification
arm from baseline to week 12 as compared to the arm B (arm
A: +109 cells/µL, arm B +49,5 cells/µL p= 0.009), this trend
was confirmed at week 48 (arm A: +46 cells/µL, arm B: -40
cells/µL from baseline, p= 0.025) [Figure 2 D]. A same trend
was observed in PP analysis at week 12 (arm A: +109 cells/µL,
arm B: +49.5 cells/µL from baseline, p= 0.007) and week 48
(arm A: +46 cells/µL, arm B: -70 cells/µL from baseline, p=
0.003).
HIV RNA quantification
In a population of 33 patients (18 in ARM A; 15 in ARM B)
HIV RNA was quantified by ultrasensitive PCR, which was able
to detect down to 1 copy/mL. In ARM A the median number of
HIV-RNA copies/ml was 2 (IQR: <1-9.5) at T0; the same
situation was observed in ARM B (median number copies/mL
2; IQR: <1-11). In ARM A the median number of HIV-RNA
copies/mL was 3 (IQR: <1-10.5) at week 48, whereas it was <1
(IQR: <1-<1) in the arm B. A statistical significant reduction of
HIV-RNA copies/mL was seen in arm B from T0 to W48 (p= .
020), whereas no change was observed in arm A. At baseline,
these viruses were: n. 14 CXCR4-tropic and n. 15 CCR5-tropic,
without differences in median ultrasensitive HIV-RNA
quantification.
Efficacy of MVC intensification
At week 12 among 78 patients with available data a
percentage of 64.3% of patients in arm A vs 38.9% of patients
in arm B satisfied the simple endpoint without statistical
significance (p=0.24, OR= 2.11, 95% CI from 0.61 to 7.31),
23.8% of patients in arm A vs. 25.0% of patients in arm B
satisfied the composite endpoint without statistical significance
(p=0.619, OR=0.76, 95% CI from 0.26 to 2.24). At week 48 a
percentage of 62.2% of 45 patients in arm A vs 35.6% of 45
patients in arm B satisfied the simple endpoint without
statistical significance (p=0.076, OR= 2.53, 95% CI from 0.91
to 7.07), 37.8% of patients in arm A vs 24.4% of patients in arm
B satisfied the composite endpoint without statistical
significance (p=0.236, OR=1.76, 95%CI 0.69-4.45) (Table 2).
All ORs were adjusted for CD4+ cells at baseline.
In the ITT analysis, both the simple and composite endpoints
were satisfied by 15/55 (27.3%) of patients with CD4+ cells <
200 cell/µL at baseline. In these subgroup of patients the OR
Figure 1.  Flow chart illustrating the entire study population.  
doi: 10.1371/journal.pone.0080157.g001
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was 3.93 (p=0.048, 95%CI 1.01-15.28). In the PP analysis the
scenario was similar to the ITT analysis with the exception of a
statistical significant achievement of the simple endpoint at
week 48 (OR=3.64; p=0.042, 95%CI 1.05-12.64) (Table 3).
Virological analysis between the study arms
Viral failure was defined as detection of HIV-RNA above the
detection threshold confirmed by at least one other following
measurement. It was observed in 3 patients: 2 in arm B and 1
in arm A. In particular, one patient in arm B showed detectable
HIV-RNA values below 200 cp/mL from baseline to week 36
and the other one got a viral load of 1,130 cp/mL at week 12.
The patient with viral failure in arm A at week 48 was censored
in the PP analysis at this time point because of an adverse
event which led to HAART interruption.
Genotypic tropism test gave a positive result on PBMCs in
51 patients (arm A: 26, arm B: 25) at baseline: 25 were CCR5-
tropic and 26 were CXCR4-tropic. Among all patients with a
CCR5 tropism, the simple and composite endpoints were
achieved with no statistical significance (p= 0.54, OR: 1.46 CI
0.44-4.91, p= 0.743, OR: 0.81 CI 0.22-2.93
respectively).Patients with CD4+ cell count less than 200
cells/µL at baseline with a CCR5 tropism got the simple and
opposite endpoints with the same statistical significance (p=
0.760, OR: 1.30 [0.25-6.84]). The intensification with MVC
corresponded to an increase in CD4 cell counts >200 cells/µL
(simple end-point) when the entire cohort of 51 patients was
considered (p= 0.023).
Immunological analyses
These analyses were conducted in the entire ITT population.
T-cell immunephenotype.  Between T0 and w12, both arm
A and arm B displayed no changes in the proportion of naive
CD45RA+CD62L+CD4+T-cells, with no substantial changes at
w48. In particular, the percentage of naive CD45RA+CD62L
+CD4+T-cells between T0 and W12 in arm A was: 14.50
[6.7-19.85]% vs 8.6 [2.9-15.7]%, p=.49; in arm B: 8.5
[3.3-15.5]% vs 6.6 [3.1-12.7]%, p=.91. At week 48 the
percentage was in arm A, 6 [2-10.9]%, p=.64 and in arm B,
5.05 [1-10.65]%, p=.81. No changes over time in the proportion
of CD4+ naive T-cells, expressing CD45RA and CD62L was
shown in Arm B and Arm A (Figure 3A).
Table 1. Baseline characteristics at randomization in the ITT analysis population.
  CTRL MVC  
  N=45 N=45 p
CDC A/B 19 (42,2) 27 (60,0) .140
 C 26 (57,8) 18 (40,0)  
Sex Male 41 (91,1) 33 (73,3) .051
 Female 4 (8,9) 12 (26,7)  
AZT No 39 (86,7) 41 (91,1) .502
 Yes 6 (13,3) 4 (8,9)  
Cotrimoxazole No 26 (57,8) 21 (46,7) .291
 Yes 19 (42,2) 24 (53,3)  
ddI+TDF No 45 (100) 45 (100) -
HCVAb No 29 (64,4) 32 (71,1) .499
 Yes 16 (35,6) 13 (28,9)  
HIV+duration Years 11 (1-27) 12,5 (2-25) .777
CD4 @ BL  170 (30-470) 191 (50-326) .134
CD8 @ BL  731 (71-1.840) 566 (60-1.209) .040
Nadir CD4  40 (5-193) 51 (1-160) .709
VL Log10 1,59 (1,28-1,84) 1,69 (1,28-1,69) .436
VL<50 cp/mL duration Months 36 (12-204) 37 (12-168) .949
HAART duration Months 63,5 (12-228) 103 (12-225) .189
CD4 <200/μL duration Months 33 (2-216) 40 (0-225) .995
HAART regimen NNRTI 11 (24,44 %) 14 (31,11%) .480
 PI 28 (62,22%) 26 (57,78%) .667
 PI+RAL 5 (11,11%) 2 (4,44%) .238
 RAL 0 (0%) 2 (4,44%) .153
 Others 1 (2,22%) 1 (2,22%) .000
CTRL: controls; MVC: maraviroc; AZT: zidovudine; ddI: didanosine; TDF: tenofovir; BL:baseline; cp: copies; mL: milliliters; μL: microliters; HAART: highly active antiretroviral
therapy; NRTI: Nucleoside Reverse Transcriptase Inhibitor; PI: protease inhibitor; NNRTI: Non-nucleoside Reverse Transcriptase Inhibitor; RAL: raltegravir; VL: HIV-RNA.
Numbers are N (%) or median (min-max). Chi-square test was used for comparisons.
*= HAART regimen: NNRTI = Backbone + NNRTI; PI = Backbone + PI; RAL = Any HAART regimen containing RAL, with or without standard backbone, but without PI;
Other = Only NRTIs-based regimens.
doi: 10.1371/journal.pone.0080157.t001
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Similarly, no changes were seen in naïve CD45RA+CD62L
+CD8+ in the two study groups at w12 and w48. In arm A at
T0, 7.9 [4.5-14.8]% vs at w12, 6.7 [1.5-12]%, p=.46; in arm B:
T0, 5.1 [2.8-15.1]% vs w12, 5.5 [3.4-11.8]%, p=.85 and at w48
in arm A: 2.9 [1.4-6]%, p=.25 and in arm B: 4.1 [1.8-5.8]%, p=.
47 (Figure 3B).
As for CD45RA-CD4+ memory T-subset, arm A and arm B
patients displayed no changes over time: arm A: T0, 67.4
[59.8-80.4]%, w12, 83.3 [74.9-89.2]%, w48, 71.6 [60.4-78.8]
p=.08 for T0 vs w12, p=1 for T0 vs w48. Arm B: T0, 78.9
[69.8-85.9]%, w12, 80.9 [64.5-87.3]%, w48, 67.80
[53.7-84.1]%, p=.97 for T0 vs w12, p=.37 for T0 vs w48. At T0,
Figure 2.  Plasma CD4+/CD8+ count and overtime change at baseline, week 12, and week 48 in the two study arms in the
intention to treat analysis.  A CD4+ count at baseline at week 12 and week 48 in arm A and B on the ITT analysis. CD4+ ITT
analysis evidenced: in arm A a median count of 192 cell/µL at baseline, 212 cells/µL at week 12 and 223 cells/ µL at week 48; in
arm B a median count of 169 cell/µL at baseline, 175 cells/µL at week 12 and 169 cells/µL at week 48. Box-plots (25% and 75%
values) are presented.
B CD4+ count change from baseline at week 12 and week 48 in the two study arms in the intention to treat analysis. The vertical
lines represent the standard deviation.
C CD8+ count at baseline at week 12 and week 48 in arm A and B on the ITT analysis. CD8+ ITT analysis evidenced: in arm A a
median count of 580 cells/µL at baseline, 634 cells/µL at week 12 and 585 cells/µL at week 48; in arm B a median count of 725
cells/µL at baseline, 681 cells/µL at week 12 and 687 cells/µL at week 48. Box-plots (25% and 75% values) are presented.
D CD8+ count change from baseline at week 12 and week 48 in the two study arms in the intention to treat analysis. The vertical
lines represent the standard deviation.
doi: 10.1371/journal.pone.0080157.g002
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arm A seemed to have higher levels of CD45RA-CD4+ as
compared to arm B (p=.052), no other inter-group differences
at w12 and w48 were shown (p=.65; p=.91, respectively
(Figure 3C).
No changes in the proportion of CD45RA-CD8+ were
observed between T0 and w12 in arm A (48.75 [36.7-72.8]% vs
57.1 [43.5-79.9]%, p=.12) and arm B (57.1 [46.1-68.5]% vs
54.7 [48.9-69.1]%, p=.68. A similar trend was seen at w48 (arm
A: 51.9 [33.9-65.8]%, p=.74; arm B: 47.80 [37.5-57.8]%, p=.22
(Figure 3D).
T-cells activation and proliferation.  Arm A displayed an
increased proportion of activated HLA-DR+CD38+CD4+ from a
median of 6.1 (2.9-11.33)% at baseline to 8.2 (3.7-13.5)% at
w12 to 27.4 (9.3-51.7)% at w48, reaching significance only at
w48 (p=.47, p=.047; respectively, whereas no changes in HLA-
DR+CD38+CD4+ were shown in Arm B (T0, 8.1 [3.6-19.5] %;
w12, 4 [2.8-9.4]%; w48, 20.6 [10.7-44.2]%; p=.29 for T0 vs
w12; p=.17 for T0 vs w48 (Figure 4A). No changes in the
proportion of activated HLA-DR+CD38+CD8+ between T0, w12
and w48 was seen in arm A (T0, 4.2 [2.3-11]%; w12 5.9
[3.5-11.5]%; w48 18.9 [8.9-36.9]% p=.64 for T0 vs w12; p=.11
Table 2. Immunological recovery as primary endpoint in the ITT analysis.
 At W 12 At W 48
 CD4>200/µL CD4>200/µL and recovery from baseline >25% CD4>200/µL CD4>200/µL and recovery from baseline >25%
 p OR 95%CI p OR 95%CI p OR 95%CI p OR 95%CI
ARM B ARM A .24 2.11 .61-7.31 .619 0.76 .26-2.24 .076 2.53 .91-7.07 .236 1.76 .69-4.45
Differences in simple and composite endpoints between arm A and arm B were assessed at week 12 and week 48 in the intention-to-treat (ITT) analysis adjusted with the
CD4 cell count at baseline. W: week; OR: odds ratio; CI: confidence interval; μL: microliters; ARM A: HAART + MVC; ARM B: HAART.
doi: 10.1371/journal.pone.0080157.t002
Table 3. Immunological recovery as primary endpoint in the PP analysis.
 At W 12 At W 48
 CD4>200/µL CD4>200/µL and recovery from baseline >25% CD4>200/µL CD4>200/µL and recovery from baseline >25%
 p OR 95%CI p OR 95%CI p OR 95%CI p OR 95%CI
ARM B ARM A .160 2.49 .70-8.91 .995 1.00 .32-3.11 .042 3.64 1.05-12.64 .120 2.36 .80-4.45
Differences in simple and composite endpoints between arm A and arm B were assessed at week 12 and week 48 in the per protocol (PP) analysis adjusted with the CD4
cell count at baseline. W: week; OR: odds ratio; CI: confidence interval; μL: microliters; ARM A: HAART + MVC; ARM B: HAART.
doi: 10.1371/journal.pone.0080157.t003
Figure 3.  Naive and memory T-cell phenotypes in Immunological Non Responders with and without HAART intensification
with MVC.  A. Percentage of naive CD45RA+CD62L+CD4+ T-cells. B. Percentage of naïve CD45RA+CD62L+CD8+ T-cells. C.
Percentage of memory CD45RA-CD4+ T-cells. D. Percentage of memory CD45RA-CD8+ T-cells.
The vertical lines represent median and interquartile ranges (25th and 75th percentiles).
doi: 10.1371/journal.pone.0080157.g003
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for T0 vs w48) and in arm B (T0,6.2 [2.5-10.7]%; w12 2.8
[1.5-6.9]%; w48 20.4 [13.3-30.2]%, p=.13 for T0 vs w12; p=.07
for T0 vs w48). At T12, arm A showed higher levels of HLA-DR
+CD38+CD8+ as compared to arm B (p=.038); no other inter-
group differences were shown at T0 and w48 (p=.95; p=.79;
respectively) (Figure 4B).
Between T0 and w12, no changes in Ki67+CD4+ were
observed in arm A (6.7 [3.9-13.9]% vs 6.1 [2.6-13.1]%, p=.42),
whereas arm B displayed an increase in Ki67+CD4+ (7.2
[3.3-11.2[% vs 12.1 [3.5-18.7]%;p=.048). No changes between
T0 and w48 in the two study groups were seen (arm A: 7.9
[5.5-13.8]%, p=.22 ; arm B: 4.7 [2.6-10.5]% p=.99) (Figure 4C).
With regard to Ki67+CD8+ no changes were seen in the two
study groups at w12 (arm A: 4 [2.4-9.1]% vs 4.1 [2.8-7.4]%, p=.
45; arm B: 3.7 [0.9-7.5]% vs 4.6 [2.6-7.7]%, p=.69) and w48
(arm A: 2.9 [1.4-6]%, p=.81; arm B: 4.1 [1.8-5.8]%, p=.16)
(Figure 4D).
IL-7/IL-7R system.  Arm A displayed an increasing trend in
CD127+CD4+ T-cells, close to statistical significance at w12
(T0, 69 [54.9-82.3]%, w12, 74.2 [58.1-82.8]%, w48 80.9
[63.2-89.3]%; p=.055 for T0 vs w12; p=.46 for T0 vs w48),
whereas no changes was shown over time in arm B (T0, 59.2
[41.2-81.1], w12, 65.5 [52.4-70.4]%, w48, 80.7 [62.3-83.4]%,
p=.39 for T0 vs w12, p=.16 forT0 vs w48) (Figure 5A).
Between T0 and w12, both arm A and arm B reduced the
proportion of CD127+CD8+ (Arm A: 54.2 [36.9-76.9]% vs 53.2
[40.1-75.9]%; p=.055; Arm B: 56.1 [42.9-71.5]% vs 40.3
[32.3-52.2]%; p=.016), with arm A displaying higher
CD127+CD8+ T-cells as compared to arm B at w12 (p=.034),
despite similar baseline levels (p=.96). At w48, the
CD127+CD8+ reduction was no longer significant in arm A
(29.5 [22.8-42.6]%; p=.31) as well as in arm B (38.1
[32.5-58.5]%; p=.07), with arm A still maintaining a trend to
higher CD127+CD8+ (p=.08) (Figure 5B).
Interestingly, while arm A displayed a significant increase of
circulating IL-7 at w48 (T0, 3.3 [2.2-15.5] pg/mL vs w12 3.3
[1.7-6] pg/mL; p=.47;vs w48 7.8 [5.2-12.2] pg/mL; p=.01 no
changes were observed in arm B(T0, 3.6 [1.8-7.04] pg/mL vs
w12, 3.4 [1.5-10.4] pg/mL; p=.94; vs w48 6.43 [3.6-10.5]
pg/mL; p=.23 (Figure 5C).
Figure 4.  T-cells activation and proliferation in Immunological Non Responders with and without HAART intensification
with MVC.  A-B. T-cell activation defined as the co-expression of HLA-DR and CD38 on CD4+ and CD8+.
C-D. T-cell proliferation defined as the expression of Ki67 on CD4+ and CD8+.
The vertical lines represent median and interquartile ranges (25th and 75th percentiles).
doi: 10.1371/journal.pone.0080157.g004
Figure 5.  IL-7/IL-7R system in Immunological Non Responders with and without HAART intensification with MVC.  A.
Percentage of CD127+CD4+ T-cells. B. Percentage of CD127+CD8+ T-cells. C. Plasma levels of IL-7.
The vertical lines represent median and interquartile ranges (25th and 75th percentiles).
doi: 10.1371/journal.pone.0080157.g005
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Discussion
Our study hypothesized a possible role of MVC in enhancing
an immunological recovery in HIV-1 infected patients with a
stable viral load suppression on HAART but with a poor CD4+
count recovery after several years of antiretroviral treatment.
In our study, we observed that HAART intensification with
MVC didn’t lead to a significant increase of the CD4+ count. In
particular we didn’t observe any particular differences between
arm A and B at week 12 and 48 with the exception of a slight
increase of the CD4+ cells count in arm A at week 12 which
was not confirmed at week 48. A CD4+ T-cells recovery at the
early stage of MVC intensification was reported in other
studies.
Massanella et al [21] demonstrated that naïve HIV- infected
patients got a significant CD4+ count gain at week 12 when
HAART was intensified with MVC. This trend was not
confirmed at week 48. Cossarini et al [22] demonstrated a
significant increase of CD4+ cells in multi-experienced patients
who intensified HAART with MVC versus those on HAART
+darunavir/ritonavir.
A temporary increase of the CD4+ cells during the first period
of MVC intake could be explained by a possible reduction of
activated CCR5+ T-cells as a result of the CCR5 co-receptor
blockage associated with viral suppression. This situation can
promote a temporary CD4+ cell release from the lymphoid
reservoir to plasma by a type of “redistribution” phenomenon.
Another explanation could be that MVC blockage of the co-
receptor can lead to a longer survival of CD4+ cells by
modulating the apoptotic process or some other unknown
mechanism as shown in a study lead by Wilkin et al. [23]
HIV-RNA ultrasensitive quantification didn’t seem to be
influenced by MVC intake over-time. A significant decrease of
HIV-RNA was seen at W48 in ARM B; although the sample of
patients was limited compared to the entire study cohort. This
data may be explained by improving adherence within the
control group after the enrollment period of the study.
Some interesting results among the immunological markers
should be cautiously interpreted due to inflation of type I errors
caused by multiplicity.
We didn’t find any change of naïve (CD45RA+) and memory
(CD45RA-) CD4+ cells. Differently an increase of activation
markers expression on CD4+ T-cells, HLA-DR and CD38, was
seen at week 12 and better at week 48 (p=0.047). This finding
confirmed what Hunt et al [24] had already demonstrated. In
their study a population of “immunological non-responders” that
intensified a HAART regimen with MVC showed an increase of
the cellular activation both in the CD4+ and CD8+ cells of
peripheral blood and more significantly in gut mucosa samples.
They also observed an increased expression of CCR5 on
CD4+ and CD8+ cells suggesting that compensatory increases
in CCR5 ligands might activate macrophages and that T cells
through alternative chemokine receptors should be further
explored. Hunt and colleagues studied the effect of MVC on
MIP1β and evidenced an increase in its level over-time which
returned to baseline upon MVC cessation [24].
We found a significant increase of CD8÷ cells in the
intensification arm at week 12(p= 0.009) and week 48
(p=0.025). Immunological analyses performed on CD8 didn’t
show any particular change in the naïve and memory CD8+
cells. The analysis of cellular activation of these cells through
evaluation of HLA-DR and CD38 showed an increased
expression of these markers in arm A at week 12 but not at
week 48. Our observation was concordant with what Hunt et al
had described. A more powerful action of MVC on CD8+ cells
can be justified by a higher presence of CCR5 coreceptor on
CD8+ than on CD4+ cells [25]. Blockage of CD8+ cells
migration from peripheral blood to the tissues would allow their
pool expansion. This had been observed in our study at week
12 and week 48. This conclusion has not been supported by
other studies where a reduction of CD8+cells activation and
loss of monocytes were seen in a population using MVC as
intensification [26] or as a component of HAART [27]. A further
consideration on the increase in CD8+ lymphocytes is that their
redistribution could indeed represent an improvement of the
immune system without mirroring an increased viral production.
We did not observe any change of the proliferation marker
Ki67+ at week 48, although a significant increase of this marker
was unexpectedly seen at week 12 in arm B (p=.048). One
limitation of the results for this parameter was the small size of
the samples available for T-cell proliferation measurements;
further analyses should be performed to confirm these
preliminary data.
An increase of IL-7 level in arm A could suggest an effect of
MVC in maintaining T-lymphocyte homeostasis through T-
lymphocyte production in a milieu of stable turnover of
peripheral T-cells, as evidenced by the absence of Ki67+
change over time, although Bonferroni analysis did not confirm
a significant difference between the 2 arms. Whether or not
raised IL-7 translates into increased de novo T-cell production
[28,29] is not clear from our data, as we didn’t evaluate thymic
output.
We also found an increased expression of IL-7 receptor on
CD4+ cells in MVC-receiving patients; the finding of an inverse
trend on CD8+ cells suggest diverse IL-7R regulation on
circulating CD4+ and CD8+ upon MVC administration. This
different behavior of IL-7R on CD8+ may be caused by a
possible down-regulation of cell-surface receptor expression in
the presence of raised levels of plasma IL-7. Further studies
are warranted to better unravel the diverse regulation of IL-7/
IL-7R axis upon MVC administration and by investigating the
effect of MVC on IL-7R expression inducers and inhibitors [30].
MVC intensification of HAART did not show a significant
efficacy in satisfying both the simple and composite endpoints
with the intention to treat analysis adjusted with the CD4+ cells
at baseline, although a trend towards the achievement of the
simple endpoint was seen at week 48 in the on treatment
analysis (p=0.076). The estimates of odds ratios resulted quite
identical also when applying LOCF methods in the ITT analysis
(data not shown). Of note, the subjects in the control arm
achieved a CD4+ response higher than expected when the
study was designed. Nevertheless, an interesting observation
came up when we stratified the analysis according to patients
with CD4+ cell count less than 200 cells/µL at baseline: we
found the statistical significant achievement of simple and
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composite endpoints (p=0.048, OR 3.93, 95% confidence
interval from 1.01 to 15.28).
Other studies tried to evaluate the immune system response
to a HAART intensification with MVC in immunological non-
responder patients [18,23,31]. All of these studies did not have
a control arm, exhibited discordant results in increasing CD4+
cell counts, and had an observation period shorter than our
study.
In our study, MVC was discontinued in 2/47 subjects and
demonstrated a satisfactory control of viral replication:
virological failures were seen equally in arms A and B.
There are several limitations to this study. This was a
randomized trial which did not imply a placebo drug intake in
the control arm. Changes in the immune response in arm A
could have been influenced by a sort of “placebo effect” due to
the consciousness of taking a forth drug in the regimen.
Immunophenotyping analyses were performed on cryo-
preserved PBMCs: the freezing process may have damaged
the expression of cell surface proteins. Data on CD8 subsets
would be interesting; unfortunately central vs effector memory
CD8 phenotyping could not be addressed because there was
no remaining biological material at the time when the original
samples were taken. A number of confounding factors, such as
different sample processing, shipping conditions, samples
storage and lab blood tests data collected from several centers
could have interfered with the quality of results. Moreover, 20%
of our patients discontinued the study for several reasons and
this could have impaired the final results of the protocol.
Although CD4+ T-cell counts improved in the MVC
intensification arm, the primary end-points were not satisfied in
this population of immunological non responders. MVC showed
to be efficient in increasing the CD8+ cell count; this might
mean a better recovery of the cell-mediated immunity and
therefore a reduction of AIDS and non-AIDS related events.
Further analyses are needed to confirm this last hypothesis.
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